Bausch & Lomb Corp (BLCO) · Oct 13, 2026 · Exec change
CEO transition — Saunders departs; Appio interim CEO; FY 2026 EBITDA guidance expected higher
Bausch + Lomb’s CEO departure creates a leadership reset just as preliminary results point to another 2026 EBITDA guidance increase.
Bausch + Lomb is pursuing broad-based eye-health growth across contact lenses, consumer products, pharmaceuticals, and surgical devices; it had already raised 2026 guidance in July and reaffirmed it in August.
The operating signal is improving, but the upgrade is still only preliminary. Based on preliminary third-quarter results, management expects to raise full-year adjusted EBITDA excluding acquired IPR&D guidance. 〔0〕 That is an incremental positive versus the standing story because guidance had already been raised and then reaffirmed, but the filing gives no new range or amount. Details are deferred until the October 28 earnings release. 〔1〕
| Filing item | Detail |
|---|---|
| Saunders separation payment | $75.5 million (Separation Agreement) |
| Attorneys’ fee reimbursement | Up to $50,000 (Separation Agreement) |
| Transition assistance | 90 days (Separation Agreement) |
| Continued group health-plan eligibility | Two years (Separation Agreement) |
The CEO change is the counterweight to the better outlook. Brent Saunders is leaving immediately, while Thomas Appio becomes interim CEO and continues running controlling shareholder Bausch Health. 〔2〕 Appio has prior Bausch + Lomb operating experience, which supports continuity, but an interim appointment leaves the permanent succession question unresolved. The filing says the departure was not caused by a dispute, so it does not establish an operational breakdown. 〔3〕
The separation terms make this more than a routine personnel notice. Saunders receives a $75.5 million lump-sum cash payment, while all outstanding equity awards are forfeited. The cash cost is clear, but cancellation of the awards limits future dilution and removes the prior CEO’s ongoing equity participation; the filing does not provide enough financial context to judge the payment’s size relative to annual cash generation.
Bottom line: The business momentum is pointing higher, but the sudden CEO reset adds execution and succession uncertainty. The event is genuinely mixed until October 28 shows how much the EBITDA outlook actually rises and whether the transition looks controlled rather than disruptive.
Q3 results and updated guidance, October 28
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!